RT @MedResearchNSW: Brian is living proof of the importance of clinical trials in saving lives. Three years ago he was diagnosed with an in….

RT @pawel_sobczuk: My abstract is already submitted. And yours?.

RT @anzsarcoma: Congratulations to Hayden Snow and David Gyorki on the publication of their latest paper in collaboration with the @TARPSWG….

In Boston wth my friend and colleague Eve at BIO25. Busy, interesting day, many meetings! Lots of trials for Australian cancer patients✌️ @NSWHealth @OmicoAustralia.

RT @ProfRAScolyer: Tour de Cure is an amazingly committed and hard-working cancer community. It was fun to attend their annual Snow Ball ev….

RT @VivekSubbiah: 🧬 TWEETORIAL/X'torial: Why Every Rare Cancer Patient Deserves Molecular Profiling 🧬.1/15 🚨 Here's a shocking fact: Rare c….

RT @VivekSubbiah: 🚨 @ASCO #ASCO25 was absolutely incredible! 🧬✨ So many groundbreaking advances in oncology and exciting publications that….

RT @VivekSubbiah: 🚨 Wow! #ASCO25 @ASCO was absolutely massive!.10 @NEJM papers published simultaneously 👉 all practice-changing studies !….

RT @herbloong: #Honoured and #humbled to have been awarded #FASCO and #ASCO25. My thanks to my friends and colleagues for your overwhelming….

RT @OmicoAustralia: Different roles, shared purpose: Omico loves @RareCancers's drive to make things better for people living with cancer.….

Absolutely wonderful talk for the Big Ideas seminar seriesby @Karen_Canfell on eliminating cervical cancer. Kudos! @OmicoAustralia @UNSW @Sydney_Uni.

RT @OmicoAustralia: 📰 Omico’s May newsletter is out now. Want to keep up with our work to advance precision oncology?.Our newsletter bring….

RT @OmicoAustralia: While #InternationalClinicalTrialsDay has just passed, the importance of clinical trials — and the partnerships that ma….

Check out this work by @RareCancers looking from feedback. @OmicoAustralia.

RT @OmicoAustralia: 📺 Tonight on ABC’s #AustralianStory 📺 Join Samuel Johnson and #LoveYourSister Foundation on their extraordinary mission….

One of the many things about large scale precision oncology programs: they enable discovery of new entities. EP300::VGLL3 rhabdomyosarcoma: a potential distinct indolent adult rhabdomyosarcoma subtype - ESMO Rare Cancers @OmicoAustralia @UNSW.

RT @ProfRAScolyer: Last weekend, Katie & I also had great fun from socialising in Victoria. We even managed to catch up with many old & new….

RT @schoffski:

RT @DrLizConnolly: 🧬 Genetic Predisposition in Sarcoma. Up to 20% #sarcoma may be assoc. with predisposition genes. In our 📝 we review evid….